IN-VIVO EFFECTS OF 4-AMIDINOINDAN-1-ONE 2'-AMIDINOHYDRAZONE (CGP 48664A) AND ALPHA-DIFLUOROMETHYLORNITHINE (DFMO) ON L1210 GROWTH, CELL-CYCLE PHASE DISTRIBUTION AND POLYAMINE CONTENTS

被引:18
作者
DORHOUT, B
TEVELDE, RJ
FERWERDA, H
KINGMA, AW
DEHOOG, E
MUSKIET, FAJ
机构
[1] Central Laboratory for Clinical Chemistry, University Hospital Groningen, Groningen
关键词
D O I
10.1002/ijc.2910620615
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We studied the in vivo effects of 4-amidinoindan-1-one 2'-amidinohydrazone (CGP 48664A), alpha-difluoromethylornithine (DFMO) and a combination of CGP 48654A-DFMO on tumor growth, cell-cycle phase distribution and polyamine contents. DBA-2, mice were inoculated i.p. with 10(5) L1210 cells on day 0, treated i.p. on days 1-4 and killed on day 5. As compared to controls, CGP 48664A, DFMO and the CGP 48664A-DFMO combination reduced L1210 cell numbers by 33, 43 and 85%, respectively. CGP 48664A did not affect cell-cycle phase distribution. DFMO and the CGP 48664A-DFMO combination caused a moderate and a heavy accumulation in G(0)/G(1)- and G(2)/M-phases, respectively. Compared with controls, the CGP 48664A-DFMO combination reduced putrescine, spermidine and total polyamines, but did not affect spermine. Compared with CGP 48664A, the CGP 48664A-DFMO combination caused lower putrescine and total polyamines, higher spermine, but no change in spermidine. Compared with DFMO, the CGP 48664A-DFMO combination caused higher putrescine and spermidine, lower spermine, but no change in total polyamine levels. We conclude that CGP 48664A potentiates the cystostatic effect of DFMO in vivo. The resulting growth inhibition is accompanied by an accumulation in G(0)/G(1)- and G(2)/M-phases and a reduction of putrescine and spermidine. The data suggest that perturbed polyamine composition rather than reduced spermidine or total polyamine pool size causes a profound growth inhibition. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:738 / 742
页数:5
相关论文
共 22 条
[1]   SYNERGISTIC ANTILEUKEMIC EFFECT ON 2 POLYAMINE SYNTHESIS INHIBITORS - HOST SURVIVAL AND CELL-CYCLE KINETIC-ANALYSIS [J].
ASK, A ;
PERSSON, L ;
OREDSSON, SM ;
HEBY, O .
INTERNATIONAL JOURNAL OF CANCER, 1986, 37 (03) :465-470
[2]   CYTOSTASIS INDUCED IN L1210 MURINE LEUKEMIA-CELLS BY THE S-ADENOSYL-L-METHIONINE DECARBOXYLASE INHIBITOR 5'-([(Z)-4-AMINO-2-BUTENYL]METHYLAMINO)-5'-DEOXYADENOSINE MAY BE DUE TO HYPUSINE DEPLETION [J].
BYERS, TL ;
GANEM, B ;
PEGG, AE .
BIOCHEMICAL JOURNAL, 1992, 287 :717-724
[3]   FLOW CYTOMETRIC MEASUREMENT OF TOTAL DNA CONTENT AND INCORPORATED BROMODEOXYURIDINE [J].
DOLBEARE, F ;
GRATZNER, H ;
PALLAVICINI, MG ;
GRAY, JW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (18) :5573-5577
[4]   IN-VIVO GROWTH-INHIBITION OF L1210 LEUKEMIA BY 4-AMIDINOINDAN-1-ONE 2'-AMIDINOHYDRAZONE (CGP 48664A), A NEW INHIBITOR OF S-ADENOSYLMETHIONINE DECARBOXYLASE [J].
DORHOUT, B ;
VELDE, RJT ;
FERWERDA, H ;
KINGMA, AW ;
DEHOOG, E ;
MUSKIET, FAJ .
INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (02) :214-217
[5]   INTERFERENCE WITH S-PHASE AND G2-PHASE PROGRESSION BY POLYAMINE SYNTHESIS INHIBITORS [J].
HEBY, O ;
ANDERSSON, G ;
GRAY, JW .
EXPERIMENTAL CELL RESEARCH, 1978, 111 (02) :461-464
[6]  
HEBY O, 1980, POLYAMINES BIOMEDICA, P17
[7]   MICROBIAL-FLORA IN THE GASTROINTESTINAL-TRACT ABOLISHES CYTOSTATIC EFFECTS OF ALPHA-DIFLUOROMETHYLORNITHINE INVIVO [J].
HESSELS, J ;
KINGMA, AW ;
FERWERDA, H ;
KEIJ, J ;
VANDENBERG, GA ;
MUSKIET, FAJ .
INTERNATIONAL JOURNAL OF CANCER, 1989, 43 (06) :1155-1164
[8]   POLYAMINES - FROM MOLECULAR-BIOLOGY TO CLINICAL-APPLICATIONS [J].
JANNE, J ;
ALHONEN, L ;
LEINONEN, P .
ANNALS OF MEDICINE, 1991, 23 (03) :241-259
[9]   CELLULAR CHARACTERIZATION OF A NEW IRREVERSIBLE INHIBITOR OF S-ADENOSYLMETHIONINE DECARBOXYLASE AND ITS USE IN DETERMINING THE RELATIVE ABILITIES OF INDIVIDUAL POLYAMINES TO SUSTAIN GROWTH AND VIABILITY OF L1210 CELLS [J].
KRAMER, DL ;
KHOMUTOV, RM ;
BUKIN, YV ;
KHOMUTOV, AR ;
PORTER, CW .
BIOCHEMICAL JOURNAL, 1989, 259 (02) :325-331
[10]   ORNITHINE DECARBOXYLASE AS AN ENZYME TARGET FOR THERAPY [J].
MCCANN, PP ;
PEGG, AE .
PHARMACOLOGY & THERAPEUTICS, 1992, 54 (02) :195-215